Table 3.
The data of patients at last follow-up in different groups.
| IgAN with impaired renal function |
IgAN with normal | ||
|---|---|---|---|
| Ischemic sclerosis group (n = 77) |
Crescent group (n = 25) |
renal function (n = 100) |
|
| Follow-up time (months) | 61 | 58 | 51 |
| At time of biopsy | |||
| Hypertension (N, %) | 0 | 0 | 0 |
| Proteinuria (g/24h) | 0.67 ± 0.31 | 0.68 ± 0.32 | 0.47 ± 0.28 |
| Scr (μmol/L) | 140 ± 52 | 147 ± 88 | 80 ± 20 |
| eGFR (ml/min) | 52.5 ± 7.3 | 51.7 ± 5.9 | 92.8 ± 27.1 |
| Last follow up | |||
| Hypertension (N, %) | 25 (32.5%)a* | 6 (24.0%)a* | 8 (8.0%) |
| Proteinuria (g/24h) | 0.78 ± 0.21 | 1.30 ± 0.32a,b* | 0.61 ± 0.30 |
| Scr (μmol/L) | 160 ± 48 | 196 ± 98a**,b* | 83 ± 20 |
| eGFR (ml/min) | 47.5 ± 8.3 | 37.7 ± 10.0a**,b* | 91.5 ± 31.2 |
| Doubling of Scr (N, %) | 4 (5.2%) | 6 (24.0%)a**,b* | 2 (2.0%) |
| Corticosteroid treatment (N,%) | 1 (1.3%) | 4 (16.0%)a,b* | 3 (3.0%) |
Scr: serum creatinine; eGFR: estimated GFR.
*p < 0.05, **p < 0.01. aversus IgAN with normal renal function group. bversus ischemic sclerosis group.